6 results
1. To assess the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's disease (AD).2. To assess the pharmacokinetics (PK) of ABBV-8E12 in subjects with early AD.The exploratory objectives of this study are:• To…
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in patients of all ages with mild (FVIII level between > 5% and < 40%) or moderate hemophilia A (FVIII level between >= 1% and…
The primary objective of this study is:To evaluate the efficacy of a regimen containing GS 9350-boosted Atazanavir versus ritonavir-boosted atazanavir each administered with emtricitabine/tenofovir disoproxil fumarate in HIV 1 infected,…
Study MO41787 will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 mg/kg Q2W for a period of 52 weeks in previously untreated patients (PUPs) and minimally treated patients (MTPs) at study…
1. To assess the efficacy of ABBV-8E12 in slowing disease progression (cognitive and functional impairment) in subjects with Early Alzheimer's Disease (AD) as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB).2. To assess the…
Primary objectiveTo determine whether individualized pharmacokinetic (PK)-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the - proportion of patients without treated bleeds (6 months before and after intervention…